Venttura Bioceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.80 Cr
as on 15-07-2024
- Paid Up Capital ₹ 3.84 M
as on 15-07-2024
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 5.96%
(FY 2021)
- Profit 25.74%
(FY 2021)
- Ebitda 76.85%
(FY 2021)
- Net Worth -13.46%
(FY 2021)
- Total Assets -26.17%
(FY 2021)
About Venttura Bioceuticals
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.80 Cr and a paid-up capital of Rs 3.84 M, as per Ministry of Corporate Affairs (MCA) records.
Uday Kulkarni and Rajas Kulkarni serve as directors at the Company.
- CIN/LLPIN
U01403MH2013PTC248436
- Company No.
248436
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Sep 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Venttura Bioceuticals Private Limited offer?
Venttura Bioceuticals Private Limited offers a wide range of products and services, including Multivitamin Syrup & Drops, Iron Folic Acid Syrup, Dog Accessories, Dietary Supplements, Omega 3 Capsule, Veterinary Medicines, Dog Medicines, Nutraceuticals, Allopathic Immunity Booster, Milk & Dairy Products.
Who are the key members and board of directors at Venttura Bioceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Uday Kulkarni  | Director | 23-Sep-2013 | Current |
| Rajas Kulkarni | Director | 23-Sep-2013 | Current |
Financial Performance and Corporate Structure Insights of Venttura Bioceuticals.
Venttura Bioceuticals Private Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 5.96% increase. The company also saw a substantial improvement in profitability, with a 25.74% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Venttura Bioceuticals?
Unlock access to Venttura Bioceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Venttura Bioceuticals?
Venttura Bioceuticals has a workforce of 22 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Venttura Bioceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venttura Bioceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
